Treating all U.S.-based patients with hepatitis B virus (HBV) would significantly decrease disease burden, according to data presented at the 2021 AASLD The Liver Meeting, held virtually (abstract 30).
Furthermore, if programs are put in place to decrease the annual price of HBV care, the strategy could become highly cost-effective, or even result in cost savings, the investigators reported.
According to modeling conducted for the study, there were approximately 1.83 million cases of HBV in the